35 research outputs found
Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems.
Edelfosine is a synthetic alkyl ether phospholipid that represents a promising class of antitumor agents. However, analytical methods to measure these type compounds are scarce. The lack of a reliable methodology to quantify edelfosine is a major problem in ongoing and scheduled preclinical and clinical trials with this drug. We evaluated the applicability of high-performance liquid chromatography–mass spectrometry to determine edelfosine in biological samples and polymeric delivery systems. Sample pre-treatment involved polymer precipitation or cell lysis with methanol. HPLC separation was performed on an Alltima RPC18 narrow-bore column and edelfosine quantification was done by electrospray ionization mass spectrometry (ESI-MS) using positive ion mode and selected ion monitoring. Assays were linear in the tested range of 0.3–10 μg/ml. The limit of quantification was 0.3 ng/sample in both matrices, namely biological samples and polymeric delivery systems. The interassay precision ranging from 0.79 to 1.49%, with relative errors of −6.7 and 12.8%. Mean extraction recovery was 95.6%. HPLC–ESI-MS is a reliable system for edelfosine analysis and quantification in samples from different sources, combining advantages of full automation (rapidity, ease of use, no need of extensive extraction procedures) with high analytical performance and throughput
New methodologies to characterize the effectiveness of the gene transfer mediated by DNA-chitosan nanoparticles
In this work three DNA-chitosan nanoparticle formulations (Np), differing in the
molecular weight (MW; 150 kDa, 400 kDa, and 600 kDa) of the polysaccharide, were prepared
and administered by two different administration routes: the hydrodynamics-based procedure
and the intraduodenal injection. After the hydrodynamic injection, DNA-chitosan nanoparticles
were predominantly accumulated in the liver, where the transgene was expressed during at least
105 days. No signifi cant infl uence of MW was observed on the levels of luciferase expression.
The curves of bioluminescence versus time obtained using the charge-coupled device (CCD)
camera were described and divided in three phases: (i) the initial phase, (ii) the sustained
release step and (iii) the decline phase (promotor inactivation, immunological and physiological
processes). From these curves, which describe the transgene expression profi le, the behavior of
the different formulations as gene delivery systems was characterized. Therefore, the following
parameters such as Cmax (maximum level of detected bioluminescence), AUC (area under the
bioluminescence-time curve) and MET (mean time of the transgene expression) were calculated.
This approach offers the possibility of studying and comparing transgene expression kinetics
among a wide variety of gene delivery systems. Finally, the intraduodenal administration of
naked DNA permitted the gene transfer in a dose dependent manner quantifi able with the CCD
camera within 3 days. Nevertheless, the same administration procedure of the three formulations
did not improve the levels of transgene expression obtained with naked DNA. This fact could
be explained by the rapid physiological turn-over of enterocytes and by the ability of chitosan
nanoparticles to control the DNA release
Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method
OBJECTIVES:
The aim of this work was to develop and validate an HPLC method for gentamicin quantification in different types of biological samples such as animal tissues and cellular material and also in pharmaceuticals.
METHODS:
Poly(lactide-co-glycolide) microparticles (MP) of gentamicin (PLGA 502H MP), THP-1 cells, and plasma and tissue samples of mice treated with the antibiotic either free or loaded into PLGA 502H MP were processed by a simple preparation procedure, subjected to chromatography on a reversed-phase column and measured by mass spectrometry detection. The developed method was compared with bioassay and fluorimetric assay methods previously used for gentamicin determination.
RESULTS:
The HPLC method was linear over the ranges 40-800 ng/mL and 0.1-100 microg/mL and showed good accuracy (average accuracy < 5.59%) and reproducibility (CV < 6.13%). Encapsulation of gentamicin in PLGA 502H MP was determined by the three methods. Good correlation was observed between bioassay (reference method) and HPLC. Extra- and intracellular in vitro antibiotic accumulation was determined by bioassay and chromatography. Both methods gave similar extracellular concentrations but the HPLC-MS technique demonstrated an improved accuracy (5.59% versus 14%) and precision (6.13% versus 15%) compared with bioassay. However, only the HPLC-MS method was sensitive enough to detect the drug, intracellularly and in tissues.
CONCLUSIONS:
All these data favour the use of chromatography-mass spectrometry as a versatile technique not only suitable for gentamicin quantification loaded in drug delivery systems, but also sensitive and specific enough for in vivo and intracellular studies
Modeling of the In Vivo Antinociceptive Interaction between an Opioid Agonist, (+)-O-Desmethyltramadol, and a Monoamine Reuptake Inhibitor, (—)-O-Desmethyltramadol, in Rats
The pharmacokinetic-pharmacodynamic (pk-pd) characterization of the in vivo antinociceptive interaction between (+)-O-desmethyltramadol [(+)-M1] and (-)-O-desmethyltramadol [(-)-M1], main metabolites of tramadol, was studied in three groups of rats. (+)-M1 and (-)-M1, both with different pd properties, were studied under steady-state and nonsteady-state conditions, depending on the group. Plasma drug concentration and antinociception were simultaneously measured in each animal by using an enantioselective analytical assay and the tail-flick test, respectively. Respiratory depression also was evaluated in another series of experiments according to the same experimental conditions. The pk behavior was similar for both enantiomers and no significant (P >.05) interaction between two compounds was found at this level. However, a significant (P .05) respiratory effects were seen during or after (+)-M1 and (-)-M1 administration
Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres.
The aim of the work was to develop biodegradable microspheres for controlled delivery of the somatostatin analogue vapreotide and maintenance of sustained plasma levels over 2–4 weeks after a single injection in rats. Vapreotide was microencapsulated into end-group capped and uncapped low molecular weight poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) by spray-drying and coacervation. Microspheres were prepared from single and blended (1:1) polymer types. The microparticles were characterized for peptide loading, in vitro release and pharmocokinetics in rats. Spray-drying and coacervation produced microspheres in the size range of 1–15 and 10–70 μm, respectively, and with encapsulation efficiencies varying between 46% and 87%. In vitro release of vapreotide followed a regular pattern and lasted more than 4 weeks, time at which 40–80% of the total dose were released. Microspheres made of 14-kDa end-group uncapped PLGA50:50 or 1:1 blends of this polymer with 35 kDa end-group uncapped PLGA50:50 gave the best release profiles and yielded the most sustained plasma levels above a pre-defined 1 ng/ml over approximately 14 days. In vitro/in vivo correlation analyses showed for several microsphere formulations a linear correlation between the mean residence time in vivo and the mean dissolution time (r=0.958) and also between the amount released between 6 h and 14 days and the AUC6h–14d (r=0.932). For several other parameters or time periods, no in vitro/in vivo correlation was found. This study demonstrates that controlled release of the vapreotide is possible in vivo for a duration of a least 2 weeks when administered i.m. to rats. These results constitute a step forward towards a twice-a-month or once-a-month microsphere-formulation for the treatment of acromegaly and neuroendocrine tumors
A simple and robust high-performance liquid chromatography coupled to a diode-array detector method for the analysis of genistein in mouse tissues
A simple liquid-liquid extraction procedure and quantification by high-performance liquid chromatography (HPLC) method coupled to a diode-array detector (DAD) of genistein (GEN) was developed in various mouse biological matrices. 7-ethoxycoumarin was used as internal standard (IS) and peaks were optimally separated using a Kinetex C18 column (2.6 µm, 150 mm X 2.10 mm I.D.) at 40 ºC with an isocratic elution of mobile phase with sodium dihydrogen phosphate 0.01M in water at pH 2.5 and methanol (55:45, v/v), at a flow rate of 0.25 mL/min. The injection volume was 10 µL. In all cases, the range of GEN recovery was higher than 61%. The low limit of quantification (LLOQ) was 25 ng/mL. The linearity of the calibration curves was satisfactory in all cases as shown by correlation coefficients >0.996. The within-day and between-day precisions were <15% and the accuracy ranged in all cases between 90.14 and 106.05%. This method was successfully applied to quantify GEN in liver, spleen, kidney and plasma after intravenous administration of a single dose (30 mg/Kg) in female BALB/C mice
Poly(D,L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice
Drug delivery systems containing gentamicin were studied as a treatment against experimental brucellosis in mice. Micro- and nanoparticles prepared by using poly(D,L-lactide-coglycolide) (PLGA) 502H and microparticles made of PLGA 75:25H were successfully delivered to the liver and the spleen, the target organs for Brucella melitensis. Both polymers have the same molecular weight but have different lactic acid/glycolic acid ratios. Microparticles of PLGA 502H and 75:25H released their contents in a sustained manner, in contrast to PLGA 502H nanoparticles, which were degraded almost completely during the first week postadministration. The values of the pharmacokinetic parameters after administration of a single intravenous dose of 1.5 mg/kg of body weight of loaded gentamicin revealed higher areas under the curve (AUCs) for the liver and the spleen and increased mean retention times (MRTs) compared to those for the free drug, indicating the successful uptake by phagocytic cells in both organs and the controlled release of the antibiotic. Both gentamicin-loaded PLGA 502H and 75:25H microparticles presented similar pharmacokinetic parameter values for the liver, but those made of PLGA 75:25 H were more effective in targeting the antibiotic to the spleen (higher AUCs and MRTs). The administration of three doses of 1.5 mg/kg significantly reduced the load associated with the splenic B. melitensis infection. Thus, the formulation made with the 75:25H polymer was more effective than that made with 502H microspheres (1.45-log and 0.45-log reductions, respectively, at 3 weeks posttreatment). Therefore, both, pharmacokinetic and pharmacodynamic parameters showed the suitability of 75:25H microspheres to reduce the infection of experimentally infected mice with B. melitensis
Bioadhesive properties of Gantrez nanoparticles
Bioadhesive nanoparticles have been proposed as carriers for the oral delivery of poorly available drugs and facilitate the use of this route. This work summarises some experiments describing the bioadhesive potential of Gantrez nanoparticles fluorescently labeled with rhodamine B isothiocyanate. The adhesive potential of Gantrez was found to be stronger when folded as nanoparticles than in the solubilised form. Conventional nanoparticles displayed a tropism for the upper areas of the gastrointestinal tract, with a maximum of adhesion 30 min post-administration and a decrease in the adhered fraction along the time depending on the given dose. The cross-linkage of nanoparticles with increasing amounts of 1,3-diaminopropane stabilised the resulting carriers and prolonged their half-life in an aqueous environment; although, the adhesive capacity of nanoparticles, the intensity and the relative duration of the adhesive interactions within the gut as a function of the cross-linking degree. Finally, nanoparticles were coated with either gelatin or albumin. In the first case, the presence of gelatin dramatically decreased the initial capacity of these carriers to interact with the gut mucosa and the intensity of these phenomenons. In the latter, bovine serum albumin coated nanoparticles (BSA-NP) showed an important tropism for the stomach mucosa without further significant distribution to other parts of the gut mucosa
Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice
Objective: To study the toxicity and activity of two new amphotericin B formulations: poly(ε-caprolactone)
nanospheres coated with poloxamer 188 (AmB-NP) and mixed micelles with the same surfactant (AmB-MM).
Materials and methods: The toxicity of these formulations was evaluated in erythrocytes, J774.2 macrophages
and LLCPK1 renal cells, as well as in mice. Activity was determined in clinical isolates and in neutropenic
mice. Mice were made neutropenic with 5-fluorouracil, infected with Candida albicans and treated
with the antifungal formulations for three consecutive days. AmB association in cells and accumulation in
kidneys and liver of animals was quantified by HPLC.
Results: Both formulations decreased between 8- and 10-fold the MIC of the polyene against clinical isolates
of C. albicans. However, their activity was lower than or equal to that of AmB-deoxycholate when it was
assessed against C. albicans-infected macrophages. When given as a single intravenous dose in mice,
AmB-MM and AmB-NP had an LD50 of 9.8 and 18.6 mg/kg, respectively, compared with 4 mg/kg for AmBdeoxycholate.
Comparison of residual infection burdens in the liver and kidneys showed that AmB-deoxycholate
(0.5 mg/kg) was more effective and faster in eradicating yeast cells than polymeric formulations.
This fact can be related to a lower AmB accumulation inside macrophages and in liver and kidneys (about 1.5
mg drug/g tissue) of mice, compared with those detected for AmB-deoxycholate (4 mg drug/g). Overall, the
efficacy of these formulations at 2 mg/kg was equal to that of AmB-deoxycholate at 0.5 mg/kg.
Conclusions: AmB-MM and AmB-NP decreased the in vivo antifungal activity of AmB, and higher concentrations
were therefore necessary to obtain a similar therapeutic effect. However, these higher concentrations
were achievable owing to the reduced toxicity of these formulations
Chemical and biological factors in the control Brucella and Brucellosis
Brucellosis is a highly contagious bacterial zoonosis that affects millions of people worldwide. Brucella is highly infectious, especially when aerosolized. The infection induces severe protracted diseases, which are both debilitating and incapacitating, hence, Brucella melitensis has been considered a potential biological warfare agent. In the battle against Brucella, it is crucial to know its chemical-structure and biochemistry-metabolic characteristics. It is well known that Brucella, as well as many other intracellular bacterial pathogens, has evolved to survive and even proliferate within monocytes and macrophages cells. Depending on the route of entry (complement, Fc, lectin or fibronectin receptors), the fate of the bacteria will vary; it may even segregate from the endocytic route towards the endoplasmic reticulum. This intracellular “non regular” behaviour of Brucella makes treatment difficult. Most antibiotics, although effective in vitro, do not actively pass through cellular membranes, or, once inside, may not reach the discrete intracellular niche where the bacteria is hidden. Therefore, complete eradication of the microorganisms is difficult to achieve, and the incidence of relapses is rather high. Taking these data into consideration, this review will evaluate the past, current and new trends in the control of brucellosis, paying special attention to the drug delivery systems as potential vectors for targeting these intracellular sites where the organisms are located